• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    1/14/26 5:28:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    upxi_8k.htm
    0001775194false00017751942026-01-092026-01-09iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

     

    FORM 8-K

    _________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 9, 2026

    _______________________________

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    001-40535

     

    83-3378978

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3030 N. Rocky Point Drive, Suite 420

    Tampa, FL 33607

    (Address of Principal Executive Offices) (Zip Code)

     

    (727) 287-2800

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.00001

     

    UPXI

     

    NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Upexi, Inc. (the “Company”) entered into a Securities Purchase Agreement dated January 9, 2026 (the “Purchase Agreement”) with Hivemind Validation Master Fund (the “Investor”), pursuant to which the Company issued to the Investor a secured convertible promissory note in the original principal amount of approximately $36 million (the “Note”), in exchange for the transfer and contribution of 265,500 units of Solana (SOL) in the form of locked SOL (the “Digital Assets”).

     

    As consideration for the issuance of the Note, the Investor transferred and assigned to the Company all of the Investor’s beneficial and economic ownership interest in the Digital Assets. Due to the locked and staked nature of the Digital Assets, the transfer was effected by assignment of beneficial and economic ownership and custodial acknowledgments and did not require an immediate on-chain transfer, validator exit, or unstaking of the Digital Assets.

     

    The Note bears interest at a rate of 1.0% per annum, payable quarterly in cash, and matures on January 9, 2028. The outstanding principal amount of the Note is not payable in cash under any circumstances. At maturity, or upon acceleration following an event of default, to the extent the Note has not been converted in full, the Investor is entitled to receive a pro rata return of the Digital Assets corresponding to the outstanding principal balance of the Note at such time. The Investor bears the risk that the market value of the Digital Assets at maturity or acceleration may be less than the outstanding principal balance of the Note.

     

    The principal amount of the Note is convertible, in whole or in part, at the option of the Investor at any time, into shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a fixed conversion price of $2.39 per share, subject to customary adjustments, ownership limitations, and other conditions set forth in the Note.

     

    The Note also provides for forced conversion under certain circumstances, subject to satisfaction of specified conditions, including trading price and liquidity thresholds, the effectiveness of a resale registration statement covering the shares issuable upon conversion, and the absence of events of default.

     

    In connection with the issuance of the Note, the Company entered into a Security Agreement dated January 9, 2026 with the Investor (the “Security Agreement”), pursuant to which the Company granted the Investor a continuing first-priority security interest in and to the Digital Assets, all related digital asset accounts and wallets, associated rights and credentials, and proceeds thereof, to secure the Company’s obligations under the Note. The Security Agreement provides for custody and control arrangements, including account control agreements, and restricts the transfer, sale, or other disposition of the Digital Assets while the Note remains outstanding, subject to limited exceptions.

     

    The foregoing summaries of the Note, Purchase Agreement, and the Security Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are attached hereto as Exhibits 4.1, 10.1,  and 10.2 respectively, to this Current Report on Form 8-K and are hereby incorporated by reference into this Item 1.01.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth under Item 1.01 of this Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 7.01 Regulation FD Disclosure

     

    In connection with the negotiation of the Securities Purchase Agreement and related secured convertible note transaction with Hivemind Validation Master Fund, the Company previously shared with the investor, in a limited and non-public context, certain internal, unaudited information regarding the Company’s asset position and capital structure, including an internal calculation of the Company’s estimated modified net asset value (“mNAV”) as of January 9, 2026. This disclosure is being furnished to satisfy the Company’s obligations under Regulation FD.

     

     
    2

     

     

    Based on the mNAV calculation, management estimated the Company’s adjusted treasury net asset value as of January 9, 2026 to be approximately $234.4 million, representing a fully-loaded modified net asset value of approximately 0.92x.

     

    The mNAV calculation reflects internal management estimates and assumptions regarding the Company’s digital asset holdings, outstanding indebtedness, cash and cash equivalents, and capitalization assuming conversion of outstanding convertible securities. The calculation is non-GAAP, subject to significant uncertainty and volatility, and assumes conversion scenarios that may not occur. The Company does not undertake any obligation to update or revise the mNAV calculation or the related estimates.

     

    The information in Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.

     

    Item 8.01 Other Events.

     

    On January 13, 2026, the Company issued a press release announcing that it entered into the Purchase Agreement. The press release describes the principal economic terms of the transaction, including the aggregate principal amount of approximately $36 million, the 1.0% interest rate payable quarterly in cash, the fixed conversion price of $2.39 per share, and the 24-month maturity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The press release also notes the Company’s expectation that the transaction will increase the Company’s Solana treasury and describes certain anticipated effects of the transaction based on management’s current assumptions and expectations, which are subject to change. The statements in the press release reflect management’s views as of the date thereof and are subject to risks, uncertainties, and assumptions, including those described elsewhere in this Current Report on Form 8-K.

     

    The foregoing description of the press release is qualified in its entirety by reference to Exhibit 99.1. The information in Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.

    Exhibit Description

    4.1

    Secured Convertible Promissory Note dated January 9, 2026 between Upexi, Inc. and Holder (as defined therein)

    10.1

     

    Securities Purchase Agreement, dated January 9, 2026, between Upexi, Inc. and Purchaser (defined therein)

    10.2

     

    Security Agreement dated January 9, 2026 between Upexi, Inc. and Secured Party (as defined therein)

    99.1

     

    Press Release of Upexi, Inc., dated January 13, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL Document)

     

     
    3

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Dated: January 14, 2026

     

    /s/ Andrew J. Norstrud

     

     

     

    Name: Andrew J. Norstrud

     

     

     

    Title: Chief Financial Officer

     

     

     
    4

     

    Get the next $UPXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Announces Pricing of $36 Million Private Placement of Convertible Note Priced Above the Market

    Transaction to Increase Solana Treasury by 12% to over 2.4 million SOL Offering is Accretive to Adjusted Solana per Share upon Conversion TAMPA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a securities purchase agreement with Hivemind Capital Partners for the purchase of a Convertible Note in exchange for locked Solana with an aggregate original principal amount of approximately $36 million (the "Note"). The Note is collateralized by the SOL used as consideration to purchase the Note. It has an interest rate of 1.0% payable on a quarterly basi

    1/13/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming January Investor Conferences

    TAMPA, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in the following January 2026 investor conferences. Details for each conference can be found below. The link to webcasted presentations can be found on our Investor Relations website here: https://ir.upexi.com/news-events/ir-calendar. 12th Annual Alpha North Capital Event ConferenceDate: January 16-18, 2026Location: Grand Hyatt Baha Mar, Nassau, BahamasAttendees: Brian Rudick, Chief Strategy OfficerType: Investor Meetings Sidoti Micro-Cap Virtual ConferenceDa

    1/9/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Moves to High-Return Treasury Strategy

    TAMPA, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, announced that it will implement a risk-adjusted high yield strategy designed to materially enhance Solana treasury returns in 2026. Upexi does not expect the implementation to cause any disruption to its Solana treasury operations. The Company believes this strategic shift will allow it to pursue improved yields in a disciplined and prudent manner, increasing operational flexibility, and strengthening alignment between treasury activities and broader corporate objectives. Upexi updated its Solana holdings, which now stand at 2,174,58

    1/7/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    1/14/26 5:28:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    1/9/26 5:20:35 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Upexi Inc.

    EFFECT - UPEXI, INC. (0001775194) (Filer)

    1/9/26 12:15:16 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care